Akebia Therapeutics, Inc.

AKBA Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
AKBA Income Statement
AKBA Balance Sheet
AKBA Cash Flow
Congress Trading

Recent trades of AKBA by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
AKBA Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
AKBA Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
AKBA Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by AKBA's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $280,000 Oct 21, 2024 Issue: Medicare/Medicaid Health Issues
  • $260,000 Jul 22, 2024 Issue: Medicare/Medicaid Health Issues
  • $370,000 Apr 22, 2024 Issue: Medicare/Medicaid Health Issues
  • $230,000 Jan 22, 2024 Issue: Medicare/Medicaid Health Issues
  • $240,000 Oct 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $310,000 Jul 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $310,000 Jan 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $300,000 Oct 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $320,000 Jul 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $320,000 Apr 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $270,000 Jan 20, 2022 Issue: None
  • $300,000 Oct 20, 2021 Issue: None
  • $400,000 Jul 20, 2021 Issue: None
  • $340,000 Apr 20, 2021 Issue: None
  • $310,000 Jan 21, 2021 Issue: None
  • $340,000 Oct 20, 2020 Issue: None
  • $510,000 Jul 20, 2020 Issue: None
  • $450,000 Apr 20, 2020 Issue: None
  • $300,000 Jan 21, 2020 Issue: None
  • $420,000 Oct 21, 2019 Issue: Medicare/Medicaid Health Issues
  • $650,000 Jul 22, 2019 Issue: Medicare/Medicaid Health Issues
  • $440,000 Apr 22, 2019 Issue: Medicare/Medicaid Health Issues
  • $140,000 Jan 22, 2019 Issue: Budget/Appropriations Medicare/Medicaid Health Issues
  • $90,000 Oct 22, 2018 Issue: Budget/Appropriations Medicare/Medicaid Health Issues
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Jan. 30, 2024
  • Patent Title: Compositions and methods for treating anemia Jan. 02, 2024
  • Patent Title: Compositions and methods for treating anemia Dec. 19, 2023
  • Patent Title: Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid Aug. 01, 2023
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Jul. 04, 2023
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid Dec. 13, 2022
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Aug. 30, 2022
  • Patent Title: Compositions and methods for treating anemia May. 10, 2022
  • Patent Title: Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides Mar. 08, 2022
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Jul. 20, 2021
  • Patent Title: Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides Aug. 11, 2020
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Aug. 04, 2020
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Mar. 24, 2020
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Jun. 18, 2019
  • Patent Title: Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides Apr. 02, 2019
  • Patent Title: Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof Dec. 11, 2018
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Dec. 11, 2018
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Jun. 05, 2018
  • Patent Title: Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides Oct. 03, 2017
  • Patent Title: Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Jul. 11, 2017
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Mar. 21, 2017
  • Patent Title: Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides Sep. 29, 2015
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Jan. 27, 2015
  • Patent Title: Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer Oct. 21, 2014
  • Patent Title: Prolyl hydroxylase inhibitors and method of use May. 13, 2014
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Dec. 03, 2013
  • Patent Title: Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase Aug. 20, 2013
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Jan. 01, 2013
  • Patent Title: Prolyl hydroxylase inhibitors and methods of use Dec. 04, 2012
  • Patent Title: N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones Mar. 13, 2012
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of AKBA in WallStreetBets Daily Discussion

AKBA News

Recent insights relating to AKBA

CNBC Recommendations

Recent picks made for AKBA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in AKBA

AKBA Top Shareholders
Shareholder
Shares Held
AKBA Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

AKBA Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view AKBA Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top